DK0595526T3 - Middel til at forbedre perifær cirkulation - Google Patents

Middel til at forbedre perifær cirkulation

Info

Publication number
DK0595526T3
DK0595526T3 DK93308301.6T DK93308301T DK0595526T3 DK 0595526 T3 DK0595526 T3 DK 0595526T3 DK 93308301 T DK93308301 T DK 93308301T DK 0595526 T3 DK0595526 T3 DK 0595526T3
Authority
DK
Denmark
Prior art keywords
alkyl group
lower alkyl
hydrogen atom
group
disease
Prior art date
Application number
DK93308301.6T
Other languages
Danish (da)
English (en)
Inventor
Hiroshi Narita
Sakae Murata
Minako Kaburaki
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of DK0595526T3 publication Critical patent/DK0595526T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • External Artificial Organs (AREA)
  • Processing Of Meat And Fish (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Vehicle Body Suspensions (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
  • Confectionery (AREA)
DK93308301.6T 1992-10-23 1993-10-19 Middel til at forbedre perifær cirkulation DK0595526T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28483492 1992-10-23

Publications (1)

Publication Number Publication Date
DK0595526T3 true DK0595526T3 (da) 1997-10-13

Family

ID=17683621

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93308301.6T DK0595526T3 (da) 1992-10-23 1993-10-19 Middel til at forbedre perifær cirkulation

Country Status (10)

Country Link
EP (1) EP0595526B1 (de)
KR (1) KR100194825B1 (de)
AT (1) ATE157874T1 (de)
CA (1) CA2108871A1 (de)
DE (1) DE69313775T2 (de)
DK (1) DK0595526T3 (de)
ES (1) ES2108832T3 (de)
GR (1) GR3024700T3 (de)
SG (1) SG48753A1 (de)
TW (1) TW273511B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101640897B1 (ko) 2015-09-16 2016-07-29 주식회사 지에이치비 주낙통 접합기 및 주낙통 접합방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590188A (en) * 1984-02-18 1986-05-20 Tanabe Seiyaku Co., Ltd. 1,5-benzothiazepine derivatives and their pharmaceutical use
US4594342A (en) * 1984-04-10 1986-06-10 Tanabe Seiyaku Co., Ltd. 1,5-benzothiazepine derivative
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
JPH01186875A (ja) * 1988-01-19 1989-07-26 Tanabe Seiyaku Co Ltd ベンゾチアゼピン誘導体の製法
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
CA2087743C (en) * 1992-02-06 1999-04-27 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation

Also Published As

Publication number Publication date
CA2108871A1 (en) 1994-04-24
ES2108832T3 (es) 1998-01-01
KR940008684A (ko) 1994-05-16
SG48753A1 (en) 1998-05-18
DE69313775T2 (de) 1998-01-22
TW273511B (de) 1996-04-01
DE69313775D1 (de) 1997-10-16
EP0595526A1 (de) 1994-05-04
ATE157874T1 (de) 1997-09-15
EP0595526B1 (de) 1997-09-10
GR3024700T3 (en) 1997-12-31
KR100194825B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
LU91943I2 (fr) Tafluprost et ses dérivés pharmaceutiquement acceptables (SAFLUTAN®)
MY115311A (en) Optically active 2 - imidazoline - 5 - one derivatives as fungicides.
DK0565721T3 (da) 1,4-Benzothiazepinderivat
ES2106573T3 (es) Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma.
PT918776E (pt) Sintese total de acilfulvenos antitumorais
ATE172463T1 (de) Pyrrolocarbazol
ATE223411T1 (de) 1-methylcarbapenem-derivate
DK0595526T3 (da) Middel til at forbedre perifær cirkulation
ES2035915T3 (es) Agentes antiarritmicos n-fenetil-aminoalquil-benzamida.
DK0476854T3 (da) Farmaceutisk komposition til at hæmme blodpladeaggregation
TW198031B (de)
ATE105565T1 (de) Pradimicinderivate.
DK653687A (da) Middel til behandling af nyresygdomme
ATE132748T1 (de) Verwendung eines dihydropyridins zur verbesserung der blutzirkulation des inneren ohres